University of Missouri, Kansas City
umkc.eduTotal trials
47
Active
8
Phase 3
4
Total enrollment
7,462
Read this sponsor's pipeline like an analyst.
Generate a written report: strategic focus, priority programs, pipeline shape, recent terminations and momentum, and the trials worth watching in the next 12 months.
~15-30 sec · cached for 24h
Pipeline matrix
Showing 2 of 2 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Liposomal bupivacaine | — | — | — | — | — | 1 | |
| Deposition of saline | — | — | — | — | — | 1 |
Next readouts
- 2025-06-01
Top conditions
- Knee Osteoarthritis2
- Multiple Sclerosis2
- Relapsing-remitting Multiple Sclerosis2
- Depression2
- Pregnancy2
- Pregnancy Complications, Cardiovascular1
- Vitamin d Deficiency1
- Type 2 Diabetes1
Frequently asked questions about University of Missouri, Kansas City
- How many clinical trials does University of Missouri, Kansas City have on ClinicalTrials.gov?
- University of Missouri, Kansas City is listed as the lead sponsor on 47 clinical trials in ClinicalTrials.gov, 8 of which are currently active (recruiting, enrolling, or ongoing).
- How many of University of Missouri, Kansas City's trials are in Phase 3?
- 4 of University of Missouri, Kansas City's trials are in Phase 3, spread across 2 active drug programs.
- What therapeutic areas does University of Missouri, Kansas City focus on?
- University of Missouri, Kansas City's most-studied conditions on ClinicalTrials.gov are Knee Osteoarthritis, Multiple Sclerosis, Relapsing-remitting Multiple Sclerosis, Depression, Pregnancy.
- When are University of Missouri, Kansas City's next clinical trial readouts?
- University of Missouri, Kansas City has 1 upcoming primary-completion readout tracked here; the soonest is “Stopping Opioid Overuse in Obstetrics to Halt Exposure Trial”, expected around 2025-06-01.